))
Episode 56 - TWITTER SPAC’S CHIP SHORTAGE PHARMA STOCKS
Série arquivada ("Feed inativo " status)
When?
This feed was archived on February 22, 2024 08:11 (
Why? Feed inativo status. Nossos servidores foram incapazes de recuperar um feed de podcast válido por um período razoável.
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 290973560 series 2818443
Conteúdo fornecido por Gavin Graham. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Gavin Graham ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Correspondent Samuel Okocha analyses the present and potential future of Twitter Inc.
From London James Athey at Aberdeen Standard Investments questions whether SPACs can continue at their current level.
From San Diego California Peter Merrick of MerrickWealth.com looks at the winners (Taiwan Semiconductor, Intel) and losers (Ford, General Motors, Toyota and Volkswagen) in the current chip shortage.
Gavin Graham dissects the pharmaceutical stock sector and the impact of vaccine news, looking at Pfizer, Johnson & Johnson, AstraZeneca, Moderna and other pharma companies.
89 episódios
Compartilhar
